A real-world case series from a Greek neuromuscular center proposes practical sequencing strategies in generalized myasthenia gravis, pairing fast-acting FcRn antagonists with long-term immune therapies. The report highlights approaches that aim to cut corticosteroid exposure while covering early control and sustained disease management through rituximab or ravulizumab, including post-operative context considerations raised by complementary commentary.